RISK ASSESSMENT METHOD FOR ACUTE CARDIOVASCULAR EVENTS

• US 20080027330A1
• Filed: 05/15/2007
• Published: 01/31/2008
• Est. Priority Date: 05/15/2006
• Status: Abandoned Application

• Current Assignee: Endothelix Co.
• Original Assignee: Endothelix, Inc.
• Inventors: Ahmadi, Naser, O'Brien, Timothy, Johnson, Mark, Jamieson, Craig, Naghavi, Morteza, Hassan, Haider
• Application Number:
  US11/749,105
• Publication Number:
  US 20080027330A1
• Time in Patent Office: Days
• US Class Current: 600/481
• CPC Class Codes: A61B 5/02 Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
• CPC Class Codes: A61B 5/318 Heart-related electrical modalities, e.g. electrocardiography [ECG]
• CPC Class Codes: A61B 8/06 Measuring blood flow measuring volume flow in general G01F, e.g. G01F1/66, G01F1/72; measuring speed of fluids in general G01P5/00

Abstract

Methods and apparatus are provided for assessing the risk of an acute cardiovascular event that includes providing an endothelial or vascular function test to identify higher risk from lower risk individuals in a population of symptomatic individuals presenting with chest pain that have inconclusive results in ECG and cardiovascular marker tests, such as a tropinin test, and are administered for triage in hospital and additional tests such as ECG exercise and nuclear stress tests. The invention further provides methods and apparatus for assessing the vascular status and response of patients in clinical trials for cardiovascular therapies.

Claims

1. A method to improve risk assessment for an acute cardiovascular event in a patient presenting with chest pain comprising performing one or more vascular structural or functional tests on the patient.

2. The method of claim 1 wherein at least one vascular functional test is a non-invasive non-imaging vascular test that measures vascular response to reactive hyperemia induced by vascular occlusive challenge.

3. The method of claim 1 wherein at least one vascular functional test is selected from the group consisting of:

DTM, BP, PWV, PWF, DFV, CLVR, ABI and combinations thereof.

4. The method of claim 1 wherein the vascular functional test is implemented using a modular functional vascular status assessment apparatus that comprises:

a CPU in electrical communication with and controlling a vascular function testing module including a digital thermal monitoring (DTM) module, a cuff management module, and a display or recorder.

5. The method of claim 4 wherein the modular functional vascular status assessment apparatus further comprises a Doppler module comprising at least one Doppler sensor.

6. The method of claim 4, wherein the DTM module comprises a plurality of temperature sensors.

7. The method of claim 4, wherein the cuff management module comprises a plurality of blood pressure cuffs and blood pressure detectors.

8. The method of claim 5, wherein the Doppler module controls a plurality of Doppler sensors.

9. The method of claim 5, wherein at least one Doppler sensor is adapted for measurement of Doppler flow velocity.

10. The method of claim 1, wherein the vascular functional test is a non-invasive coronary vasoreactivity imaging test that measures change in coronary flow and/or diameter with provocation.

11. The method of claim 10 wherein the provocation is a cold-pressor test.

12. The method of claim 1, further comprising determining a level of a marker of cardiovascular injury and/or a marker of atherosclerosis.

13. The method of claim 12, wherein the marker of cardiovascular injury comprises at least one marker selected from the group consisting of cardiac tropinins, CK-MB and CKMB isoforms, myoglobin, and the marker of cardiovascular risk comprises at least one marker selected from the group consisting of CRP (C reactive protein), I-CAM (intercellular adhesion molecule), SAP (serum amyloid P), MPO (myeloperoxidase), ADMA (asymmetric dimethylarginine), NO (nitric oxide), NO compounds/metabolites, and skin sterol.

14. The method of claim 1, wherein the vascular structural test provides a coronary calcium score.

15. The method of claim 11, wherein the vascular structural test measures a carotid artery intima-media thickness (IMT).

16. A method for identifying a high risk of an acute cardiovascular event in a patient presenting with chest pain comprising performing the following steps:

performing an EKG on the patient to determine an ST elevation;

if the ST is not elevated, performing a structural or functional atherosclerosis test on the patient to determine if further evaluation is required.

17. The method of claim 16, further comprising the step of determining a cardiovascular risk factor score for the patient.

18. A method for characterizing response to therapy in a clinical trial of a medication, device and/or drug comprising determining a micro or macro vascular function assessment for trial participants.

19. The method of claim 18, wherein the micro or macro vascular function assessment is a determined by one or more of the following tests:

DTM, BP, PWV, PWF, DFV, CLVR, and ABI.

20. A method of risk assessment in a patient presenting with a possible acute cardiovascular symptom, comprising:

determining a cardiac specific injury marker level in the patient;

if the patient is negative or equivocal for cardiac specific injury markers, performing one or more structural or functional tests for atherosclerosis on the patient; and

triage the patients with negative cardiac injury markers based on the results of the one or more structural or functional tests for atherosclerosis.

21. A computer implemented method of risk assessment in a patient presenting with a possible acute cardiovascular symptom, comprising:

determining results from one or more vascular functional tests on the patient and placing the determined results of the one or more tests into a computational dataset corresponding to the patient;

receiving a status for each of a plurality of epidemiologic risk factors and inputting the received status of the epidemiologic risk factors into the computational dataset corresponding to the patient; and

computing a combined functional and epidemiologic relative risk for the individual from the dataset corresponding to the patient.

22. The computer implemented method of claim 21, wherein the one or more vascular function tests include one or more of:

DTM, BP, PWV, PWF, DFV, CLVR, and ABI.

23. The computer implemented method of claim 21, further comprising:

receiving results from one or more structural assessments on the patient and placing the results of the one or more structural assessments into the computational dataset corresponding to the patient; and

computing a combined functional, epidemiologic, and structural relative risk for the individual from the dataset corresponding to the individual.

24. The computer implemented method of claim 23, wherein the structural assessments include determination of pathologic changes including one or more of:

increased intima medial thickness, atherosclerotic plaque formation and calcium deposits in at least one vascular bed.